Crohn's Disease (Regional Enteritis) Global Clinical Trials Review, H2, 2016
Summary
GlobalData's clinical trial report, “Crohn's Disease (Regional Enteritis) Global Clinical Trials Review, H2, 2016" provides an overview of Crohn's Disease (Regional Enteritis) clinical trials scenario. This report provides top line data relating to the clinical trials on Crohn's Disease (Regional Enteritis). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top Five Countries Contributing to Clinical Trials in Europe 11
Top Countries Contributing to Clinical Trials in North America 12
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 13
Top Countries Contributing to Clinical Trials in Central and South America 14
Clinical Trials by G7 Countries: Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials 15
Clinical Trials by Phase in G7 Countries 16
Clinical Trials in G7 Countries by Trial Status 17
Clinical Trials by E7 Countries: Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials 18
Clinical Trials by Phase in E7 Countries 19
Clinical Trials in E7 Countries by Trial Status 20
Clinical Trials by Phase 21
In Progress Trials by Phase 22
Clinical Trials by Trial Status 23
Clinical Trials by End Point Status 24
Subjects Recruited Over a Period of Time 25
Clinical Trials by Sponsor Type 26
Prominent Sponsors 27
Top Companies Participating in Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials 28
Prominent Drugs 30
Latest Clinical Trials News on Crohn's Disease (Regional Enteritis) 31
Sep 16, 2016: Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology 31
Sep 12, 2016: Celgene Announces Interim Topline Data from Trial of Investigational Oral GED-0301 in Patients with Active Crohn's Disease 32
Aug 22, 2016: 4D pharma provides clinical update on Thetanix 32
Aug 02, 2016: Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease 33
Clinical Trial Profile Snapshots 35
Appendix 542
Abbreviations 542
Definitions 542
Research Methodology 543
Secondary Research 543
About GlobalData 544
Contact Us 544
Disclaimer 544
Source 545
List Of Tables
List of Tables
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Region, 2016* 6
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 8
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 10
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 11
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, North America, Top Countries, 2016* 12
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 13
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 14
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 15
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 18
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Phase, 2016* 21
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 22
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Crohn's Disease (Regional Enteritis) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 26
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
List Of Figures
List of Figures
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 9
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 10
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 11
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 12
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 13
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 14
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, G7 Countries (%), 2016* 15
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 16
Crohn's Disease (Regional Enteritis) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 17
Proportion of Crohn's Disease (Regional Enteritis) to Gastrointestinal Clinical Trials, E7 Countries (%), 2016* 18
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 19
Crohn's Disease (Regional Enteritis) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 20
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 21
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 22
Crohn's Disease (Regional Enteritis) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 23
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 24
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 25
Crohn's Disease (Regional Enteritis) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 26
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Crohn's Disease (Regional Enteritis) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
GlobalData Methodology 543
